Process and Automation

In a lead up to The International Day of Women and Girls in Science, Pharmaceutical Technology® takes a look at the unique perspective women bring to the use of artificial intelligence in the pharmaceutical industry.

The collaboration will combine fully automated and digitalized technologies to reduce CGT manufacturing timelines to 2.5 days.

Cytiva will combine its CGT manufacturing technologies with Cellular Origins' robotic manufacturing platform.

Automation technologies provide real potential to improve responsiveness and decision-making in drug development.

Automation, miniaturization, and new software algorithms are improving throughput and accuracy.

Synaffix, a Lonza company, has licensed its ADC technology to BigHat Biosciences to be combined with the latter's ML design platform to develop new ADCs

Capturing and curating R&D data are crucial to realizing the full value of advanced analytics.

With DKK 600 million (US$87.4 million) in funding from the Novo Nordisk Foundation, the new supercomputer offers the potential to accelerate innovation in drug discovery.

The use of artificial intelligence and machine learning has the potential to provide some key benefits; however, there are still significant barriers to the implementation of these advanced technologies.

New and existing technologies, as well as a patient-centric focus, are pushing drug formulation into exciting directions.

New technologies improve efficiency and remove operator intervention.

Manual and automated inspection technologies have their own advantages and limitations.

The VIOS family of incubators are known for optimal cell growth conditions and minimal contamination risk.

Leveraging automation advancements can help improve efficiency in aseptic processing and speed up commercialization of critical drug products.

Artificial intelligence and machine learning can help overcome poor solubility and bioavailability.

Lonza’s Joe Garrity and Jerry Jiang discuss the importance of not only automating CGT manufacturing, but also standardizing across processes.

Improved efficiencies and reduced costs are clear advantages of automating drug manufacturing processes.

CGT Catapult will implement Cellular Origins' robotic platform in its Stevenage, UK, site to establish automated CGT manufacturing.

Digital transformation is allowing for better handling, analysis, and protection of vast data collection.

In a new agreement, Cellares will utilize its Cell Shuttle fully automated cell therapy manufacturing platform to manufacture select CAR-T cell therapies under development by Bristol Myers Squibb.

Effective analytics will eliminate failures, deviations, and non-conformances.

European bio/pharma companies have no choice but to invest and adapt to the evolving industry needs.

This collaboration will combine BigHat Biosciences’ AI/ML-guided Milliner platform with AbbVie's expertise in oncology and neuroscience to develop next-generation antibodies.

MilliporeSigma’s new platform combines generative AI, machine learning, and computer-aided drug-design aimed at increasing the success rate of new drugs and therapies.

Digital transformation allows for smarter and connected biomanufacturing operations.

Under this multi-year collaboration, Genentech and NVIDIA will use AI to optimize and accelerate each company’s platforms to discover and develop innovative therapeutics.

Hollie Barton, senior director, Chromatographic Services, for the PPD clinical research business of Thermo Fisher Scientific, reviews the company’s latest moves in targeting automation.

As new analytical technologies advance, insight into the twin-screw granulation process is growing.

SCHOTT now offers ViewCell, a new component meant to add flexibility to biopharmaceutical process control.

A new generation of interactive formulation development platforms can leave trial and error in the formulation process in the past.